Exozymes Inc. CEO Michael Heltzen acquired 855 shares of common stock on Aug. 25 and Aug. 26, 2026, for a total value of $6,405. The transactions were executed at prices ranging from $7.35 to $7.60 per share.
The purchases follow a prior acquisition on Aug. 19, when Heltzen bought 8,841 shares at $6.40 each, totaling $56,582. Combined, the transactions increased his direct beneficial ownership of Exozymes stock to 14,708 shares.
The filings, signed on Sept. 2, 2026, were disclosed as the company’s shares traded at $6.79, below the CEO’s recent purchase prices. InvestingPro analysis indicated the stock was trading at a Price/Book multiple of 17.25, with a reported loss of $1.20 per share over the last twelve months.
Exozymes, a pre-revenue biotechnology firm, reported a net loss of $2.88 million for Q2 2026. The company concluded the quarter with $5.65 million in cash, sufficient to support operations through the end of 2026.
